Compare III & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | III | RPID |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | 1300 | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.9M | 204.3M |
| IPO Year | 2006 | 2021 |
| Metric | III | RPID |
|---|---|---|
| Price | $4.88 | $4.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 333.6K | 160.1K |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | ★ 3.77% | N/A |
| EPS Growth | N/A | ★ 11.48 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $192,745,000.00 | $28,051,000.00 |
| Revenue This Year | N/A | $19.91 |
| Revenue Next Year | $3.63 | $21.68 |
| P/E Ratio | $36.54 | ★ N/A |
| Revenue Growth | 4.51 | ★ 24.57 |
| 52 Week Low | $2.96 | $1.86 |
| 52 Week High | $6.45 | $4.94 |
| Indicator | III | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 55.32 |
| Support Level | $4.48 | $3.03 |
| Resistance Level | $5.05 | $4.46 |
| Average True Range (ATR) | 0.19 | 0.30 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 96.00 | 72.68 |
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.